Micafungin: the US perspective.
Invasive fungal infections cause considerable morbidity and mortality in nosocomial settings and amongst immunocompromised hosts. Invasive candidiasis and aspergillosis remain the most common invasive fungal infections, with Candida spp. constituting the fourth most common bloodstream infection in the USA. Currently available antifungal therapies include the polyene, antimetabolite, allylamine, azole and echinocandin drug classes. Micafungin, approved in March 2005 by the Food and Drug Administration for use in the USA, has shown safety and efficacy for the treatment of candidiasis and aspergillosis in clinical trials in Japan, Europe and South Africa. Micafungin holds promise as a first-line treatment option for candidiasis, as well as prophylaxis against invasive fungal infections during periods of neutropenia in high-risk patients.
Zaas
Aimee K
AK
Duke University Medical Center , Department of Medicine, Division of Infectious Diseases and International Health, Durham, NC 27710, USA. aimee.zaas@duke.edu
Steinbach
William J
WJ
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D008074:Lipoproteins / Q000592:standards / Q000627:therapeutic use*; D000077551:Micafungin; D009181:Mycoses / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000592:standards / Q000627:therapeutic use*; D012449:Safety
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D000077551:Micafungin